#LCSM Transcript
Healthcare social media transcript of the #LCSM hashtag.
– ().
See #LCSM Influencers/Analytics.
| Profile | Tweet |
|---|---|
 | Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD Welcome to tonight #LCSM chat @lcsmchat where we will cover topics from #WCLC21 and #ESMO21 |
 | #LCSM Chat @lcsmchat RT @CharuAggarwalMD: Welcome to tonight #LCSM chat @lcsmchat where we will cover topics from #WCLC21 and #ESMO21 |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD I am your moderator for tonight. I am a thoracic medical oncologist at @PennCancer @PennMedicine, focusing on improving lives of patients with #LungCancer #LCSM @lcsmchat |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: I am your moderator for tonight. I am a thoracic medical oncologist at @PennCancer @PennMedicine, focusing on improving lives of patients with #LungCancer #LCSM @lcsmchat |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD Its great to see many of you here, we will get started in about 5 minutes. Remember to include #LCSM in ALL your tweets so the other chat participants can see them @lcsmchat |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: Its great to see many of you here, we will get started in about 5 minutes. Remember to include #LCSM in ALL your tweets so the other chat participants can see them @lcsmchat |
 | Janet Freeman-Daily @JFreemanDaily Hi @CharuAggarwalMD! Thanks for moderating tonight's #LCSM Chat. Looking forward to hearing about highlights from #WCLC21 and #ESMO21. |
 | Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: Hi @CharuAggarwalMD! Thanks for moderating tonight's #LCSM Chat. Looking forward to hearing about highlights from #WCLC21 and #ESMO21. |
 | kristen kimball @KimballKristen RT @JFreemanDaily: Hi @CharuAggarwalMD! Thanks for moderating tonight's #LCSM Chat. Looking forward to hearing about highlights from #WCLC21 and #ESMO21. |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Hi @CharuAggarwalMD! Thanks for moderating tonight's #LCSM Chat. Looking forward to hearing about highlights from #WCLC21 and #ESMO21. |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: I am your moderator for tonight. I am a thoracic medical oncologist at @PennCancer @PennMedicine, focusing on improving lives of patients with #LungCancer #LCSM @lcsmchat |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: Its great to see many of you here, we will get started in about 5 minutes. Remember to include #LCSM in ALL your tweets so the other chat participants can see them @lcsmchat |
 | Deb Smith 🌻🟧 @debsmithbeach Deb here from lovely NH, glad to have this info. #LCSM https://t.co/aG7zJOx22l |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD RT @JFreemanDaily: Hi @CharuAggarwalMD! Thanks for moderating tonight's #LCSM Chat. Looking forward to hearing about highlights from #WCLC21 and #ESMO21. |
| #LCSM Chat @lcsmchat I already see some of you out there. Please introduce yourselves #LCSM |
| #LCSM Chat @lcsmchat RT @debsmithbeach: Deb here from lovely NH, glad to have this info. #LCSM https://t.co/aG7zJOx22l |
| Janet Freeman-Daily @JFreemanDaily RT @debsmithbeach: Deb here from lovely NH, glad to have this info. #LCSM https://t.co/aG7zJOx22l |
 | Sanjay Mukhopadhyay @smlungpathguy @CharuAggarwalMD @lcsmchat #LCSM basement dwelling slide reader here 🙏🏾 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Tim here. #lcsm |
| #LCSM Chat @lcsmchat @debsmithbeach Hi Deb! We sure miss out on this beauty in SoCal. #lcsm |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD Our discussion for tonight will be based on 5 topics labeled T1...T5, and we encourage you to chime in using A1...A5, and don't forget the #LCSM hashtag! @lcsmchat |
| Janet Freeman-Daily @JFreemanDaily @debsmithbeach Good to see you Deb! #LCSM |
| #LCSM Chat @lcsmchat RT @smlungpathguy: @CharuAggarwalMD @lcsmchat #LCSM basement dwelling slide reader here 🙏🏾 |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: Our discussion for tonight will be based on 5 topics labeled T1...T5, and we encourage you to chime in using A1...A5, and don't forget the #LCSM hashtag! @lcsmchat |
| kristen kimball @KimballKristen Hi everyone, it's Kris (Kimball) from Boston, former caregiver, staying in touch. #LCSM |
| #LCSM Chat @lcsmchat @smlungpathguy @CharuAggarwalMD What would we do without our pathologists? Right, @TimAllenMDJD? #lcsm |
| Janet Freeman-Daily @JFreemanDaily @smlungpathguy @CharuAggarwalMD @lcsmchat Hi Sanjay and Tim! #LCSM |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Tim here. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Howdy, @smlungpathguy! #lcsm |
 | Cindy Barthi @cindyb1333 RT @CharuAggarwalMD: I am your moderator for tonight. I am a thoracic medical oncologist at @PennCancer @PennMedicine, focusing on improving lives of patients with #LungCancer #LCSM @lcsmchat |
 | Lung Cancer Sux @LungCancerSux Hi @CharuAggarwalMD @BrendonStilesMD ! Looking forward to an informative evening! #LCSM |
| #LCSM Chat @lcsmchat @TimAllenMDJD Hey, Tim! Hope things are improving where you are. #lcsm |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: Our discussion for tonight will be based on 5 topics labeled T1...T5, and we encourage you to chime in using A1...A5, and don't forget the #LCSM hashtag! @lcsmchat |
| #LCSM Chat @lcsmchat RT @KimballKristen: Hi everyone, it's Kris (Kimball) from Boston, former caregiver, staying in touch. #LCSM |
| #LCSM Chat @lcsmchat @KimballKristen Hey Kris! #lcsm |
| Janet Freeman-Daily @JFreemanDaily @LungCancerFaces @lcsmchat And welcome as always to my #LCSM sidekick @LungCancerFaces who's operating the @LCSMChat account tonight. |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Can't argue with @lcsmchat! #lcsm |
| #LCSM Chat @lcsmchat RT @LungCancerSux: Hi @CharuAggarwalMD @BrendonStilesMD ! Looking forward to an informative evening! #LCSM |
| Sanjay Mukhopadhyay @smlungpathguy @JFreemanDaily @CharuAggarwalMD @lcsmchat Hi Janet! Just remember: whatever goes wrong, it’s always the pathologist’s fault! #LCSM 😜 |
| #LCSM Chat @lcsmchat @LungCancerSux @CharuAggarwalMD @BrendonStilesMD Hey you! #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @LungCancerFaces @lcsmchat And welcome as always to my #LCSM sidekick @LungCancerFaces who's operating the @LCSMChat account tonight. |
| Janet Freeman-Daily @JFreemanDaily @KimballKristen Welcome Kristen! #LCSM |
| #LCSM Chat @lcsmchat RT @smlungpathguy: @JFreemanDaily @CharuAggarwalMD @lcsmchat Hi Janet! Just remember: @JFreemanDaily @CharuAggarwalMD @lcsmchat Hi Janet! Just remember: whatever goes wrong, it’s always the pathologist’s fault! #LCSM 😜 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Howdy @JFreemanDaily! #lcsm |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD Let's get started with our first topic! T1: What new targeted therapy options were presented at #WCLC21 and #ESMO21 @lcsmchat #LCSM |
| #LCSM Chat @lcsmchat @smlungpathguy @JFreemanDaily @CharuAggarwalMD No, it’s always the mother’s fault. Ask any therapist. #lcsm |
| kristen kimball @KimballKristen @JFreemanDaily Hi Janet :) #LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: Let's get started with our first topic! T1: What new targeted therapy options were presented at #WCLC21 and #ESMO21 @lcsmchat #LCSM |
 | Christina Lizaso @btrfly12 RT @lcsmchat: TODAY! #LCSM Chat 10/7 5pm PT, 8pm ET: TODAY! #LCSM Chat 10/7 5pm PT, 8pm ET: “Best in Show - #LungCancer highlights from #WCLC21 & #ESMO2021 moderated by @CharuAggarwalMD. IMPORTANT: READ MORE HERE PRIOR TO CHAT: https://t.co/vxtSQNKFfz… Please RT to spread the word! New to chats? Read this https://t.co/CPRCw8YoQ3 |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: Let's get started with our first topic! T1: What new targeted therapy options were presented at #WCLC21 and #ESMO21 @lcsmchat #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Thank you! Getting some better but more to do. #lcsm |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD A1. Before we discuss advances from #ESMO21 and #WCLC21, I want to highlight a relatively recent approval for #KRAS NSCLC, sotorasib was approved by the @FDAOncology for 2nd Line Tx of pts with KRASG12C MT NSCLC #LCSM @lcsmchat https://t.co/P3XaoipCiN |
 | NCI Cancer Stats @NCICancerStats Did you know there are two main types of #LungCancer: small cell and non-small cell? Watch our “Did you know?” video on lung cancer to learn more. https://t.co/gZjTuen3jL #LCSM |
| Sanjay Mukhopadhyay @smlungpathguy RT @CharuAggarwalMD: Let's get started with our first topic! T1: What new targeted therapy options were presented at #WCLC21 and #ESMO21 @lcsmchat #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #DynamicDuo #lcsm |
 | Joseph Steward @jsteward2930 RT @NCICancerStats: Did you know there are two main types of #LungCancer: Did you know there are two main types of #LungCancer: small cell and non-small cell? Watch our “Did you know?” video on lung cancer to learn more. https://t.co/gZjTuen3jL #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @CharuAggarwalMD: A1. Before we discuss advances from #ESMO21 and #WCLC21, I want to highlight a relatively recent approval for #KRAS NSCLC, sotorasib was approved by the @FDAOncology for 2nd Line Tx of pts with KRASG12C MT NSCLC #LCSM @lcsmchat https://t.co/P3XaoipCiN |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD A1. Approval for #Sotorasib came through based on response rate of 37%, majority of patients had received > 2 Lines of therapy. We must remember that this approval is for KRASG12C only. @kRasKickers @lcsmchat #LCSM https://t.co/eN5TKDDvgO |
| #LCSM Chat @lcsmchat @TommaHargraves Hey Tomma! #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: A1. Approval for #Sotorasib came through based on response rate of 37%, majority of patients had received > 2 Lines of therapy. We must remember that this approval is for KRASG12C only. @kRasKickers @lcsmchat #LCSM https://t.co/eN5TKDDvgO |
 | Sahba Ferdowsi DO (conciergedoc) @DrFerdowsi RT @CharuAggarwalMD: A1. Approval for #Sotorasib came through based on response rate of 37%, majority of patients had received > 2 Lines of therapy. We must remember that this approval is for KRASG12C only. @kRasKickers @lcsmchat #LCSM https://t.co/eN5TKDDvgO |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: A1. Before we discuss advances from #ESMO21 and #WCLC21, I want to highlight a relatively recent approval for #KRAS NSCLC, sotorasib was approved by the @FDAOncology for 2nd Line Tx of pts with KRASG12C MT NSCLC #LCSM @lcsmchat https://t.co/P3XaoipCiN |
| Sahba Ferdowsi DO (conciergedoc) @DrFerdowsi RT @CharuAggarwalMD: A1. Before we discuss advances from #ESMO21 and #WCLC21, I want to highlight a relatively recent approval for #KRAS NSCLC, sotorasib was approved by the @FDAOncology for 2nd Line Tx of pts with KRASG12C MT NSCLC #LCSM @lcsmchat https://t.co/P3XaoipCiN |
 | Pembrolizumab 💜🤍💚 @LauCuapa RT @AndreaAnampaG: Latin American patients are more likely to have lung cancer with EGFR mutations (Peru 🇵🇪 had 51.1%) It is important to do genotyping as they may benefit from EGFR inhibitors @Meyersonlab of @DanaFarber #Disparities #AACRdisp21 #SurvOnc #HOFellows #lcsm https://t.co/cfXl0WtOZD |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD Glad to have this option available, through @FDAOncology's #AcceleratedApproval for our patients, as yet another targeted therapy for #NSCLC @kRasKickers @lcsmchat #LCSM https://t.co/ZtiIPvmNN6 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @CharuAggarwalMD: A1. Approval for #Sotorasib came through based on response rate of 37%, majority of patients had received > 2 Lines of therapy. We must remember that this approval is for KRASG12C only. @kRasKickers @lcsmchat #LCSM https://t.co/eN5TKDDvgO |
 | Kaushal Parikh @kaushalpar A1 amivantamab data presented at #ESMO21 and #wclc21. Also approved recently for egfr ex 20 ins mut after platinum chemo. #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD RT @kaushalpar: A1 amivantamab data presented at #ESMO21 and #wclc21. Also approved recently for egfr ex 20 ins mut after platinum chemo. #LCSM |
 | Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation @RManochakian It’s Rami Manochakian. Oncologist @MayoCancerCare Joining the wonderful #LCSM chat @lcsmchat for important discussion on #LUNGCANCER updates from #WCLC21 & #ESMO21 . Session moderated by Outstanding colleague & expert @CharuAggarwalMD #CancerEducation |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: Glad to have this option available, through @FDAOncology's #AcceleratedApproval for our patients, as yet another targeted therapy for #NSCLC @kRasKickers @lcsmchat #LCSM https://t.co/ZtiIPvmNN6 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @CharuAggarwalMD: Glad to have this option available, through @FDAOncology's #AcceleratedApproval for our patients, as yet another targeted therapy for #NSCLC @kRasKickers @lcsmchat #LCSM https://t.co/ZtiIPvmNN6 |
 | Rosemary Conway @SLPChitChat RT @lcsmchat: It’s time for another #LCSM Chat! @CharuAggarwalMD will break down the most promising & important Lung Cancer research from 2 major conferences: #WCLC21 & #ESMO21. Join us this Thurs 10/7 5pm PT, 8pm ET to stay up-to-date on the “Best in Show.” Please RT to spread the word! https://t.co/XNYYcunjGu |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: A1. Before we discuss advances from #ESMO21 and #WCLC21, I want to highlight a relatively recent approval for #KRAS NSCLC, sotorasib was approved by the @FDAOncology for 2nd Line Tx of pts with KRASG12C MT NSCLC #LCSM @lcsmchat https://t.co/P3XaoipCiN |
| Janet Freeman-Daily @JFreemanDaily RT @kaushalpar: A1 amivantamab data presented at #ESMO21 and #wclc21. Also approved recently for egfr ex 20 ins mut after platinum chemo. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @kaushalpar: A1 amivantamab data presented at #ESMO21 and #wclc21. Also approved recently for egfr ex 20 ins mut after platinum chemo. #LCSM |
 | Peggy Dennis @peggyddennis @lcsmchat Peggy here from Denver #LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: A1. Approval for #Sotorasib came through based on response rate of 37%, majority of patients had received > 2 Lines of therapy. We must remember that this approval is for KRASG12C only. @kRasKickers @lcsmchat #LCSM https://t.co/eN5TKDDvgO |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: Glad to have this option available, through @FDAOncology's #AcceleratedApproval for our patients, as yet another targeted therapy for #NSCLC @kRasKickers @lcsmchat #LCSM https://t.co/ZtiIPvmNN6 |
| Kaushal Parikh @kaushalpar RT @CharuAggarwalMD: Let's get started with our first topic! T1: What new targeted therapy options were presented at #WCLC21 and #ESMO21 @lcsmchat #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD There have been other approvals! Recent approval for #Mobocertinib, which followed on the heels of approval of #Amivantamab for patients with EGFR Exon20 Insertion Mutations #WCLC21 #ESMO21 @Exon20Group @EGFRResisters #LCSM @lcsmchat |
| #LCSM Chat @lcsmchat RT @kaushalpar: A1 amivantamab data presented at #ESMO21 and #wclc21. Also approved recently for egfr ex 20 ins mut after platinum chemo. #LCSM |
 | Eric K. Singhi, MD @esinghimd @lcsmchat Eric here 👋🏽 Oncology fellow with an interest in thoracic oncology in Houston, TX. First time joining the chat! Excited to be here #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @CharuAggarwalMD: There have been other approvals! Recent approval for #Mobocertinib, which followed on the heels of approval of #Amivantamab for patients with EGFR Exon20 Insertion Mutations #WCLC21 #ESMO21 @Exon20Group @EGFRResisters #LCSM @lcsmchat |
 | erikbelleville @BellevilleErik RT @StephenVLiu: Why not block out your calendar now for the big lung cancer meetings for 2022? Even if going virtually! Sometimes it's nice to look ahead #LCSM AACR: April 8-13 (New Orleans) ASCO: June 3-7 (Chicago) ELCC: March 30-April 2 (Prague) WCLC: Aug 6-9 (Vienna) ESMO: Sept 9-13 (Paris) https://t.co/llEfNNJ31k |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD We also saw data from clincal trial of T-DxD (trastuzumab deruxtecan) in patients with #Her2 Mutant NSCLC, making this subset extremely actionable. Presented by Dr. Li, and published in @NEJM #LCSM @lcsmchat #ESMO21 https://t.co/yHgNCXPeqz |
| Lung Cancer Sux @LungCancerSux @CharuAggarwalMD @FDAOncology @kRasKickers @lcsmchat Please cover data, if any, for NSCLC without actionable targets #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD @esinghimd @lcsmchat Welcome Eric! #LCSM |
| #LCSM Chat @lcsmchat RT @RManochakian: It’s Rami Manochakian. Oncologist @MayoCancerCare Joining the wonderful #LCSM chat @lcsmchat for important discussion on #LUNGCANCER updates from #WCLC21 & #ESMO21 . Session moderated by Outstanding colleague & expert @CharuAggarwalMD #CancerEducation |
| #LCSM Chat @lcsmchat RT @peggyddennis: @lcsmchat Peggy here from Denver #LCSM |
| Janet Freeman-Daily @JFreemanDaily @peggyddennis @lcsmchat Welcome Peggy! #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: There have been other approvals! Recent approval for #Mobocertinib, which followed on the heels of approval of #Amivantamab for patients with EGFR Exon20 Insertion Mutations #WCLC21 #ESMO21 @Exon20Group @EGFRResisters #LCSM @lcsmchat |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: There have been other approvals! Recent approval for #Mobocertinib, which followed on the heels of approval of #Amivantamab for patients with EGFR Exon20 Insertion Mutations #WCLC21 #ESMO21 @Exon20Group @EGFRResisters #LCSM @lcsmchat |
| #LCSM Chat @lcsmchat RT @esinghimd: @lcsmchat Eric here 👋🏽 Oncology fellow with an interest in thoracic oncology in Houston, TX. First time joining the chat! Excited to be here #lcsm |
| Kaushal Parikh @kaushalpar A1. Also notable mention for mobo for accelerated approval last month for same indication #lcsm |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD @LungCancerSux @FDAOncology @kRasKickers @lcsmchat Yes, we will- coming up shortly! #lcsm |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: We also saw data from clincal trial of T-DxD (trastuzumab deruxtecan) in patients with #Her2 Mutant NSCLC, making this subset extremely actionable. Presented by Dr. Li, and published in @NEJM #LCSM @lcsmchat #ESMO21 https://t.co/yHgNCXPeqz |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Welcome to #lcsm @esinghimd |
| Janet Freeman-Daily @JFreemanDaily @esinghimd @lcsmchat Glad to have you with us, Eric. #LCSM |
| #LCSM Chat @lcsmchat RT @LungCancerSux: @CharuAggarwalMD @FDAOncology @kRasKickers @lcsmchat Please cover data, if any, for NSCLC without actionable targets #LCSM |
| Joseph Steward @jsteward2930 RT @CharuAggarwalMD: We also saw data from clincal trial of T-DxD (trastuzumab deruxtecan) in patients with #Her2 Mutant NSCLC, making this subset extremely actionable. Presented by Dr. Li, and published in @NEJM #LCSM @lcsmchat #ESMO21 https://t.co/yHgNCXPeqz |
| #LCSM Chat @lcsmchat RT @kaushalpar: A1. Also notable mention for mobo for accelerated approval last month for same indication #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @CharuAggarwalMD: We also saw data from clincal trial of T-DxD (trastuzumab deruxtecan) in patients with #Her2 Mutant NSCLC, making this subset extremely actionable. Presented by Dr. Li, and published in @NEJM #LCSM @lcsmchat #ESMO21 https://t.co/yHgNCXPeqz |
| Kaushal Parikh @kaushalpar RT @CharuAggarwalMD: Welcome to tonight #LCSM chat @lcsmchat where we will cover topics from #WCLC21 and #ESMO21 |
| Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation @RManochakian A1: #Mobocertinib receives accelerated approval by @FDAOncology for patients with advanced #NSCLC with #EGFR exon 20 insertion. RR: 28%, mDOR: 17.5m 2nd approved targeted Tx for these patients (other one is #amivantamab-vmjw). Both in 2nd line #LCSM @EGFRResisters |
| Sanjay Mukhopadhyay @smlungpathguy RT @CharuAggarwalMD: There have been other approvals! Recent approval for #Mobocertinib, which followed on the heels of approval of #Amivantamab for patients with EGFR Exon20 Insertion Mutations #WCLC21 #ESMO21 @Exon20Group @EGFRResisters #LCSM @lcsmchat |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @RManochakian: A1: #Mobocertinib receives accelerated approval by @FDAOncology for patients with advanced #NSCLC with #EGFR exon 20 insertion. RR: 28%, mDOR: 17.5m 2nd approved targeted Tx for these patients (other one is #amivantamab-vmjw). Both in 2nd line #LCSM @EGFRResisters |
| Rosemary Conway @SLPChitChat #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD RT @RManochakian: A1: #Mobocertinib receives accelerated approval by @FDAOncology for patients with advanced #NSCLC with #EGFR exon 20 insertion. RR: 28%, mDOR: 17.5m 2nd approved targeted Tx for these patients (other one is #amivantamab-vmjw). Both in 2nd line #LCSM @EGFRResisters |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD Use of T-DxD is associated with > ORR of 55% > median duration of response of 9.3 months, > median PFS 8.2 months > median OS 17.8 months Bottom Line- most patients benefit. It is important to test! #BioMarker Testing #LCSM @lcsmchat https://t.co/Rnf6sKQ4cM |
| #LCSM Chat @lcsmchat RT @RManochakian: A1: #Mobocertinib receives accelerated approval by @FDAOncology for patients with advanced #NSCLC with #EGFR exon 20 insertion. RR: 28%, mDOR: 17.5m 2nd approved targeted Tx for these patients (other one is #amivantamab-vmjw). Both in 2nd line #LCSM @EGFRResisters |
| Kaushal Parikh @kaushalpar RT @CharuAggarwalMD: There have been other approvals! Recent approval for #Mobocertinib, which followed on the heels of approval of #Amivantamab for patients with EGFR Exon20 Insertion Mutations #WCLC21 #ESMO21 @Exon20Group @EGFRResisters #LCSM @lcsmchat |
| Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation @RManochakian Worth noting that #Mobocertinib is an oral drug while #amivantamab-vmjw is IV. Also, they have different toxicity profiles. #LCSM |
| Janet Freeman-Daily @JFreemanDaily @LungCancerSux @CharuAggarwalMD @FDAOncology @kRasKickers @lcsmchat You can read what the topics will be in the @lcsmchat blog at https://t.co/92JI6dxOOI #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Howdy @CharuAggarwalMD! #lcsm |
| Sanjay Mukhopadhyay @smlungpathguy Mobocertinib! @CharuAggarwalMD and #LCSM bringing info from the latest oncology conferences to the folks on Twitter! So much changes so fast in lung cancer. |
| #LCSM Chat @lcsmchat @SLPChitChat Welcome, Rosemary! If anyone else is out there watching, please send us a blank tweet with #lcsm in it. |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: Use of T-DxD is associated with > ORR of 55% > median duration of response of 9.3 months, > median PFS 8.2 months > median OS 17.8 months Bottom Line- most patients benefit. It is important to test! #BioMarker Testing #LCSM @lcsmchat https://t.co/Rnf6sKQ4cM |
| #LCSM Chat @lcsmchat RT @RManochakian: Worth noting that #Mobocertinib is an oral drug while #amivantamab-vmjw is IV. Also, they have different toxicity profiles. #LCSM |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @LungCancerSux @CharuAggarwalMD @FDAOncology @kRasKickers @lcsmchat You can read what the topics will be in the @lcsmchat blog at https://t.co/92JI6dxOOI #LCSM |
| #LCSM Chat @lcsmchat RT @smlungpathguy: Mobocertinib! @CharuAggarwalMD and #LCSM bringing info from the latest oncology conferences to the folks on Twitter! So much changes so fast in lung cancer. |
| kristen kimball @KimballKristen @SLPChitChat Hi Rosemary! #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @CharuAggarwalMD: Use of T-DxD is associated with > ORR of 55% > median duration of response of 9.3 months, > median PFS 8.2 months > median OS 17.8 months Bottom Line- most patients benefit. It is important to test! #BioMarker Testing #LCSM @lcsmchat https://t.co/Rnf6sKQ4cM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD RT @smlungpathguy: Mobocertinib! @CharuAggarwalMD and #LCSM bringing info from the latest oncology conferences to the folks on Twitter! So much changes so fast in lung cancer. |
| Janet Freeman-Daily @JFreemanDaily RT @kaushalpar: A1. Also notable mention for mobo for accelerated approval last month for same indication #lcsm |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD RT @JFreemanDaily: @LungCancerSux @CharuAggarwalMD @FDAOncology @kRasKickers @lcsmchat You can read what the topics will be in the @lcsmchat blog at https://t.co/92JI6dxOOI #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @RManochakian: A1: #Mobocertinib receives accelerated approval by @FDAOncology for patients with advanced #NSCLC with #EGFR exon 20 insertion. RR: 28%, mDOR: 17.5m 2nd approved targeted Tx for these patients (other one is #amivantamab-vmjw). Both in 2nd line #LCSM @EGFRResisters |
 | Dave Bjork @bjork5 Hi friends, sorry I’m late. #lcsm |
 | Lindsay McGrath @LindsayMcGrat12 #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: Use of T-DxD is associated with > ORR of 55% > median duration of response of 9.3 months, > median PFS 8.2 months > median OS 17.8 months Bottom Line- most patients benefit. It is important to test! #BioMarker Testing #LCSM @lcsmchat https://t.co/Rnf6sKQ4cM |
| Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation @RManochakian Bottom Line- most patients benefit. It is important to test! Couldn’t have said it better @CharuAggarwalMD #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @RManochakian: Worth noting that #Mobocertinib is an oral drug while #amivantamab-vmjw is IV. Also, they have different toxicity profiles. #LCSM |
| Eric K. Singhi, MD @esinghimd @RManochakian A1. Strong point! Infusion-related reactions especially with the initial dose of amivantamab seem common #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @smlungpathguy: Mobocertinib! @CharuAggarwalMD and #LCSM bringing info from the latest oncology conferences to the folks on Twitter! So much changes so fast in lung cancer. |
| Janet Freeman-Daily @JFreemanDaily RT @lcsmchat: @SLPChitChat Welcome, Rosemary! If anyone else is out there watching, please send us a blank tweet with #lcsm in it. |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @RManochakian: Bottom Line- most patients benefit. It is important to test! Couldn’t have said it better @CharuAggarwalMD #LCSM |
| #LCSM Chat @lcsmchat As always, we are retweeting as we go from this account, so you can look back on anything that you’ve missed. We post a transcript, too. #LCSM |
| Janet Freeman-Daily @JFreemanDaily @bjork5 Welcome Dave! #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD Other drugs have been studied in this setting before (Her2 Mutant #NSCLC) - T-DxD seems to provide an advantage over others (remember no direct comparison) > Afatinib > Neratinib > Dacomitinib > Neratinib > Pyrotinib > Poziotinib #LCSM @lcsmchat |
| #LCSM Chat @lcsmchat @LindsayMcGrat12 Hi Lindsay! Thanks for joining us. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @esinghimd: @RManochakian A1. Strong point! Infusion-related reactions especially with the initial dose of amivantamab seem common #lcsm |
| #LCSM Chat @lcsmchat RT @RManochakian: Bottom Line- most patients benefit. It is important to test! Couldn’t have said it better @CharuAggarwalMD #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @CharuAggarwalMD: Other drugs have been studied in this setting before (Her2 Mutant #NSCLC) - T-DxD seems to provide an advantage over others (remember no direct comparison) > Afatinib > Neratinib > Dacomitinib > Neratinib > Pyrotinib > Poziotinib #LCSM @lcsmchat |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: Other drugs have been studied in this setting before (Her2 Mutant #NSCLC) - T-DxD seems to provide an advantage over others (remember no direct comparison) > Afatinib > Neratinib > Dacomitinib > Neratinib > Pyrotinib > Poziotinib #LCSM @lcsmchat |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD Destiny LUNG-02 represents a new standard of care for patients with #Her2Mutant #NSCLC #LCSM @lcsmchat |
| #LCSM Chat @lcsmchat RT @esinghimd: @RManochakian A1. Strong point! Infusion-related reactions especially with the initial dose of amivantamab seem common #lcsm |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: Other drugs have been studied in this setting before (Her2 Mutant #NSCLC) - T-DxD seems to provide an advantage over others (remember no direct comparison) > Afatinib > Neratinib > Dacomitinib > Neratinib > Pyrotinib > Poziotinib #LCSM @lcsmchat |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: Destiny LUNG-02 represents a new standard of care for patients with #Her2Mutant #NSCLC #LCSM @lcsmchat |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @CharuAggarwalMD: Destiny LUNG-02 represents a new standard of care for patients with #Her2Mutant #NSCLC #LCSM @lcsmchat |
| Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation @RManochakian A1: Presented at #ESMO21 @myESMO results of #CHRYSALIS-2 trial: #Amivantamab + #Lazertinib in #EGFR mutant #NSCLC post Osimertinib & post chemo. RR 21%, CBR 51%, mTTR 1.5m #LCSM @lcsmchat |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD It's time to move on! T2: What key biomarker and liquid biopsy presentations happened at #WCLC21 and #ESMO21? @lcsmchat #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @RManochakian: A1: Presented at #ESMO21 @myESMO results of #CHRYSALIS-2 trial: #Amivantamab + #Lazertinib in #EGFR mutant #NSCLC post Osimertinib & post chemo. RR 21%, CBR 51%, mTTR 1.5m #LCSM @lcsmchat |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: Destiny LUNG-02 represents a new standard of care for patients with #Her2Mutant #NSCLC #LCSM @lcsmchat |
| #LCSM Chat @lcsmchat RT @RManochakian: A1: Presented at #ESMO21 @myESMO results of #CHRYSALIS-2 trial: #Amivantamab + #Lazertinib in #EGFR mutant #NSCLC post Osimertinib & post chemo. RR 21%, CBR 51%, mTTR 1.5m #LCSM @lcsmchat |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: It's time to move on! T2: What key biomarker and liquid biopsy presentations happened at #WCLC21 and #ESMO21? @lcsmchat #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @RManochakian: A1: Presented at #ESMO21 @myESMO results of #CHRYSALIS-2 trial: #Amivantamab + #Lazertinib in #EGFR mutant #NSCLC post Osimertinib & post chemo. RR 21%, CBR 51%, mTTR 1.5m #LCSM @lcsmchat |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: It's time to move on! T2: What key biomarker and liquid biopsy presentations happened at #WCLC21 and #ESMO21? @lcsmchat #LCSM |
| Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation @RManochakian @esinghimd Indeed reaction common and strong #LCSM |
| #LCSM Chat @lcsmchat #lcsm A question from a patient |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD @peggyddennis @NEJM @lcsmchat Amazing! Thank you for paving the way! #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD A2: We have made tremendous progress in the field of #LiquidBiopsy where we now have direct clinical applications. @LeciaSequist presented on this at #WCLC21 #LCSM @lcsmchat https://t.co/N2WIHFtkGZ |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: A2: A2: We have made tremendous progress in the field of #LiquidBiopsy where we now have direct clinical applications. @LeciaSequist presented on this at #WCLC21 #LCSM @lcsmchat https://t.co/N2WIHFtkGZ |
| Dave Bjork @bjork5 @RManochakian @CharuAggarwalMD Yes 💯 to Biomarker testing! #lcsm every patient deserves access. #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: A2: A2: We have made tremendous progress in the field of #LiquidBiopsy where we now have direct clinical applications. @LeciaSequist presented on this at #WCLC21 #LCSM @lcsmchat https://t.co/N2WIHFtkGZ |
| Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation @RManochakian Indeed new standard of care. #Her2 must add/tested for among important list of other actionable mutations in #NSCLC #lcsm @lcsmchat |
| #LCSM Chat @lcsmchat RT @bjork5: @RManochakian @CharuAggarwalMD Yes 💯 to Biomarker testing! #lcsm every patient deserves access. #lcsm |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD One of the presentations is one I am proud to have been part of from our group @PennMedicine @PennCancer @EricaCarpenter1 and Dr. Thompson. We asked if early integration of #PlasmaNGS can improve delivery of targeted therapy #LCSM @lcsmchat https://t.co/8iNH2Rx7Cc |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD #TheFutureIsBright #lcsm |
| kristen kimball @KimballKristen RT @CharuAggarwalMD: A2: A2: We have made tremendous progress in the field of #LiquidBiopsy where we now have direct clinical applications. @LeciaSequist presented on this at #WCLC21 #LCSM @lcsmchat https://t.co/N2WIHFtkGZ |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Absolutely #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @RManochakian: Indeed new standard of care. #Her2 must add/tested for among important list of other actionable mutations in #NSCLC #lcsm @lcsmchat |
| Dave Bjork @bjork5 @JFreemanDaily Hey Janet! #lcsm 😊 |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD Early integration of LiquidBiopsy can improve delivery of targeted therapy, and reduce time to treat #BiomarkerTesting #WCLC21 #LCSM @lcsmchat https://t.co/9eUWehicMQ |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: One of the presentations is one I am proud to have been part of from our group @PennMedicine @PennCancer @EricaCarpenter1 and Dr. Thompson. We asked if early integration of #PlasmaNGS can improve delivery of targeted therapy #LCSM @lcsmchat https://t.co/8iNH2Rx7Cc |
| #LCSM Chat @lcsmchat RT @RManochakian: Indeed new standard of care. #Her2 must add/tested for among important list of other actionable mutations in #NSCLC #lcsm @lcsmchat |
| kristen kimball @KimballKristen RT @bjork5: @RManochakian @CharuAggarwalMD Yes 💯 to Biomarker testing! #lcsm every patient deserves access. #lcsm |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: One of the presentations is one I am proud to have been part of from our group @PennMedicine @PennCancer @EricaCarpenter1 and Dr. Thompson. We asked if early integration of #PlasmaNGS can improve delivery of targeted therapy #LCSM @lcsmchat https://t.co/8iNH2Rx7Cc |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Great @CharuAggarwalMD! #lcsm |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: Early integration of LiquidBiopsy can improve delivery of targeted therapy, and reduce time to treat #BiomarkerTesting #WCLC21 #LCSM @lcsmchat https://t.co/9eUWehicMQ |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @CharuAggarwalMD: Early integration of LiquidBiopsy can improve delivery of targeted therapy, and reduce time to treat #BiomarkerTesting #WCLC21 #LCSM @lcsmchat https://t.co/9eUWehicMQ |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: Early integration of LiquidBiopsy can improve delivery of targeted therapy, and reduce time to treat #BiomarkerTesting #WCLC21 #LCSM @lcsmchat https://t.co/9eUWehicMQ |
 | Lucia Viola MD @LuciaViola9 RT @IASLC: Surgical resection remains the gold standard for patients diagnosed w/early-stage #lungcancer; Since the early 1990s, VATS lobectomy has been acknowledged as an effective (and preferred) minimally invasive approach for lung cancer surgery. Read More: https://t.co/6wIlEKIspM #LCSM |
| Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation @RManochakian @bjork5 @CharuAggarwalMD Thx @bjork5 We can never say it often enough. Every patient (with advanced #NCSLC and soon even early stage) HAS to have full #NGS/#Biomarker testing. #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD RT @RManochakian: @bjork5 @CharuAggarwalMD Thx @bjork5 We can never say it often enough. Every patient (with advanced #NCSLC and soon even early stage) HAS to have full #NGS/#Biomarker testing. #LCSM |
| kristen kimball @KimballKristen RT @CharuAggarwalMD: One of the presentations is one I am proud to have been part of from our group @PennMedicine @PennCancer @EricaCarpenter1 and Dr. Thompson. We asked if early integration of #PlasmaNGS can improve delivery of targeted therapy #LCSM @lcsmchat https://t.co/8iNH2Rx7Cc |
| Dave Bjork @bjork5 RT @CharuAggarwalMD: A2: A2: We have made tremendous progress in the field of #LiquidBiopsy where we now have direct clinical applications. @LeciaSequist presented on this at #WCLC21 #LCSM @lcsmchat https://t.co/N2WIHFtkGZ |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Word #lcsm |
| #LCSM Chat @lcsmchat RT @RManochakian: @bjork5 @CharuAggarwalMD Thx @bjork5 We can never say it often enough. Every patient (with advanced #NCSLC and soon even early stage) HAS to have full #NGS/#Biomarker testing. #LCSM |
| Eric K. Singhi, MD @esinghimd @RManochakian @bjork5 @CharuAggarwalMD A2. So true. I’m reminded of the presentation from WCLC21 that highlighted that PCR can’t detect >40% of EGFR exon 20 insertion variants. Need NGS, especially with FDA approvals in this space. #lcsm |
| Sanjay Mukhopadhyay @smlungpathguy RT @CharuAggarwalMD: One of the presentations is one I am proud to have been part of from our group @PennMedicine @PennCancer @EricaCarpenter1 and Dr. Thompson. We asked if early integration of #PlasmaNGS can improve delivery of targeted therapy #LCSM @lcsmchat https://t.co/8iNH2Rx7Cc |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD RT @esinghimd: @RManochakian @bjork5 @CharuAggarwalMD A2. So true. I’m reminded of the presentation from WCLC21 that highlighted that PCR can’t detect >40% of EGFR exon 20 insertion variants. Need NGS, especially with FDA approvals in this space. #lcsm |
| Dave Bjork @bjork5 RT @RManochakian: @bjork5 @CharuAggarwalMD Thx @bjork5 We can never say it often enough. Every patient (with advanced #NCSLC and soon even early stage) HAS to have full #NGS/#Biomarker testing. #LCSM |
| Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation @RManochakian #LiquidBiopsy is a must for every patient with advanced #NSCLC. It gives us results sooner and it’s a simple blood test. #lcsm @lcsmchat |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD Another important paper looked at perceptions of biomarker testing across US oncology physicians @LUNGevity > There is a need for patient education > Guidelines + Best Practices to guide implementation of molecular testing #LCSM @lcsmchat https://t.co/rI1Vo0wMPT |
| Janet Freeman-Daily @JFreemanDaily RT @RManochakian: @bjork5 @CharuAggarwalMD Thx @bjork5 We can never say it often enough. Every patient (with advanced #NCSLC and soon even early stage) HAS to have full #NGS/#Biomarker testing. #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @esinghimd: @RManochakian @bjork5 @CharuAggarwalMD A2. So true. I’m reminded of the presentation from WCLC21 that highlighted that PCR can’t detect >40% of EGFR exon 20 insertion variants. Need NGS, especially with FDA approvals in this space. #lcsm |
| #LCSM Chat @lcsmchat RT @esinghimd: @RManochakian @bjork5 @CharuAggarwalMD A2. So true. I’m reminded of the presentation from WCLC21 that highlighted that PCR can’t detect >40% of EGFR exon 20 insertion variants. Need NGS, especially with FDA approvals in this space. #lcsm |
| #LCSM Chat @lcsmchat RT @RManochakian: #LiquidBiopsy is a must for every patient with advanced #NSCLC. It gives us results sooner and it’s a simple blood test. #lcsm @lcsmchat |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: Another important paper looked at perceptions of biomarker testing across US oncology physicians @LUNGevity > There is a need for patient education > Guidelines + Best Practices to guide implementation of molecular testing #LCSM @lcsmchat https://t.co/rI1Vo0wMPT |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD T3: What new ideas did #WCLC21 and #ESMO21 offer regarding adjuvant immunotherapy? #LCSM @lcsmchat |
| Janet Freeman-Daily @JFreemanDaily RT @RManochakian: #LiquidBiopsy is a must for every patient with advanced #NSCLC. It gives us results sooner and it’s a simple blood test. #lcsm @lcsmchat |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @esinghimd: @RManochakian @bjork5 @CharuAggarwalMD A2. So true. I’m reminded of the presentation from WCLC21 that highlighted that PCR can’t detect >40% of EGFR exon 20 insertion variants. Need NGS, especially with FDA approvals in this space. #lcsm |
| #LCSM Chat @lcsmchat I see you @CroixDenise! Thanks for joining us. #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @RManochakian: #LiquidBiopsy is a must for every patient with advanced #NSCLC. It gives us results sooner and it’s a simple blood test. #lcsm @lcsmchat |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: Another important paper looked at perceptions of biomarker testing across US oncology physicians @LUNGevity > There is a need for patient education > Guidelines + Best Practices to guide implementation of molecular testing #LCSM @lcsmchat https://t.co/rI1Vo0wMPT |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @CharuAggarwalMD: Another important paper looked at perceptions of biomarker testing across US oncology physicians @LUNGevity > There is a need for patient education > Guidelines + Best Practices to guide implementation of molecular testing #LCSM @lcsmchat https://t.co/rI1Vo0wMPT |
| Sanjay Mukhopadhyay @smlungpathguy I wonder how far we are from the day when circulating tumor DNA testing (instead of testing for driver mutations in biopsied tissue) will be the first, routine option in stage 4 lung cancer #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: T3: T3: What new ideas did #WCLC21 and #ESMO21 offer regarding adjuvant immunotherapy? #LCSM @lcsmchat |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @CharuAggarwalMD: T3: T3: What new ideas did #WCLC21 and #ESMO21 offer regarding adjuvant immunotherapy? #LCSM @lcsmchat |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD A3. Adjuvant Therapy is simply systemic therapy administered after surgery in an attempt to reduce risk of recurrence #LCSM @lcsmchat https://t.co/LHCPDJc17h |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @smlungpathguy: I wonder how far we are from the day when circulating tumor DNA testing (instead of testing for driver mutations in biopsied tissue) will be the first, routine option in stage 4 lung cancer #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD @smlungpathguy We will always need our pathology friends! #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @CharuAggarwalMD: A3. Adjuvant Therapy is simply systemic therapy administered after surgery in an attempt to reduce risk of recurrence #LCSM @lcsmchat https://t.co/LHCPDJc17h |
| Janet Freeman-Daily @JFreemanDaily RT @smlungpathguy: I wonder how far we are from the day when circulating tumor DNA testing (instead of testing for driver mutations in biopsied tissue) will be the first, routine option in stage 4 lung cancer #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: A3. Adjuvant Therapy is simply systemic therapy administered after surgery in an attempt to reduce risk of recurrence #LCSM @lcsmchat https://t.co/LHCPDJc17h |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: @smlungpathguy We will always need our pathology friends! #LCSM |
| Kaushal Parikh @kaushalpar A3. Impower150 paves way for atezo adj after chemo. Ques is, what pdl1 cutoff are we comfortabld with? 1% vs 50%? And is DFS enough for changing practice? #lcsm |
| Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation @RManochakian #LCSM @lcsmchat T2: What key biomarker and liquid biopsy presentations happened at #WCLC21 and #ESMO21? A2: One common message from all presentations: #BiomarkersTesting/#NgsTesting is A MUST from #LiquidBiopsy & #Tissue |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: T3: T3: What new ideas did #WCLC21 and #ESMO21 offer regarding adjuvant immunotherapy? #LCSM @lcsmchat |
| #LCSM Chat @lcsmchat RT @smlungpathguy: I wonder how far we are from the day when circulating tumor DNA testing (instead of testing for driver mutations in biopsied tissue) will be the first, routine option in stage 4 lung cancer #LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: A3. Adjuvant Therapy is simply systemic therapy administered after surgery in an attempt to reduce risk of recurrence #LCSM @lcsmchat https://t.co/LHCPDJc17h |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD Privileged to be here to help our patients, @CharuAggarwalMD #lcsm |
| #LCSM Chat @lcsmchat RT @kaushalpar: A3. Impower150 paves way for atezo adj after chemo. Ques is, what pdl1 cutoff are we comfortabld with? 1% vs 50%? And is DFS enough for changing practice? #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @kaushalpar: A3. Impower150 paves way for atezo adj after chemo. Ques is, what pdl1 cutoff are we comfortabld with? 1% vs 50%? And is DFS enough for changing practice? #lcsm |
| #LCSM Chat @lcsmchat RT @RManochakian: #LCSM @lcsmchat T2: What key biomarker and liquid biopsy presentations happened at #WCLC21 and #ESMO21? A2: One common message from all presentations: #BiomarkersTesting/#NgsTesting is A MUST from #LiquidBiopsy & #Tissue |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: Privileged to be here to help our patients, @CharuAggarwalMD #lcsm |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD #IMPOWER010 asked the question if adding immunotherapy will add benefit? #LCSM @lcsmchat https://t.co/0fLplu70F0 |
| Janet Freeman-Daily @JFreemanDaily RT @RManochakian: #LCSM @lcsmchat T2: What key biomarker and liquid biopsy presentations happened at #WCLC21 and #ESMO21? A2: One common message from all presentations: #BiomarkersTesting/#NgsTesting is A MUST from #LiquidBiopsy & #Tissue |
| Dave Bjork @bjork5 @esinghimd @RManochakian @CharuAggarwalMD 💯💯💯 #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @kaushalpar: A3. Impower150 paves way for atezo adj after chemo. Ques is, what pdl1 cutoff are we comfortabld with? 1% vs 50%? And is DFS enough for changing practice? #lcsm |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @CharuAggarwalMD: #IMPOWER010 asked the question if adding immunotherapy will add benefit? #LCSM @lcsmchat https://t.co/0fLplu70F0 |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: #IMPOWER010 asked the question if adding immunotherapy will add benefit? #LCSM @lcsmchat https://t.co/0fLplu70F0 |
| #LCSM Chat @lcsmchat Thank you for joining us tonight @DrBonillaOnc @BrainTumorDoc #lcsm |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD Dr. @HwakeleeMD presented this data at #ASCO21 and updated by @EnriquetaFelip @ESMO21 #LCSM @lcsmchat https://t.co/BG3A2juWh0 |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: #IMPOWER010 asked the question if adding immunotherapy will add benefit? #LCSM @lcsmchat https://t.co/0fLplu70F0 |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: Dr. @HwakeleeMD presented this data at #ASCO21 and updated by @EnriquetaFelip @ESMO21 #LCSM @lcsmchat https://t.co/BG3A2juWh0 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @CharuAggarwalMD: Dr. @HwakeleeMD presented this data at #ASCO21 and updated by @EnriquetaFelip @ESMO21 #LCSM @lcsmchat https://t.co/BG3A2juWh0 |
| Eric K. Singhi, MD @esinghimd @CharuAggarwalMD @lcsmchat A3. We had an update on IMPower010 at WCLC21. Adjuvant atezo improved DFS in resected stage 2-3A NSCLC. Will DFS ➡️ OS? Which subgroup of pts, based on PD-L1 %, should receive? #lcsm |
| Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation @RManochakian A3: Probable new standard of care. especially for high #PDL1. Adjuvant #Atezolizumab after adjuvant chemo for resected early stage #NSCLC #LCSM |
 | Preventive Medicine Bot @PreventiveBot RT @NCICancerStats: Did you know there are two main types of #LungCancer: Did you know there are two main types of #LungCancer: small cell and non-small cell? Watch our “Did you know?” video on lung cancer to learn more. https://t.co/gZjTuen3jL #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @esinghimd: @CharuAggarwalMD @lcsmchat A3. We had an update on IMPower010 at WCLC21. Adjuvant atezo improved DFS in resected stage 2-3A NSCLC. Will DFS ➡️ OS? Which subgroup of pts, based on PD-L1 %, should receive? #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: Dr. @HwakeleeMD presented this data at #ASCO21 and updated by @EnriquetaFelip @ESMO21 #LCSM @lcsmchat https://t.co/BG3A2juWh0 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @RManochakian: A3: A3: Probable new standard of care. especially for high #PDL1. Adjuvant #Atezolizumab after adjuvant chemo for resected early stage #NSCLC #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @esinghimd: @CharuAggarwalMD @lcsmchat A3. We had an update on IMPower010 at WCLC21. Adjuvant atezo improved DFS in resected stage 2-3A NSCLC. Will DFS ➡️ OS? Which subgroup of pts, based on PD-L1 %, should receive? #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @RManochakian: A3: A3: Probable new standard of care. especially for high #PDL1. Adjuvant #Atezolizumab after adjuvant chemo for resected early stage #NSCLC #LCSM |
| #LCSM Chat @lcsmchat Thank you for joining us @FmprZahra @jakelee0711 #lcsm |
 | Fábio Tavora, MD, PhD @fabiotavora @smlungpathguy Fabio here, #pulmonarypathologist from Brazil. I still think we can do so much and go so much deeper in tissue than #liquidbiopsy, but am hopeful the latter will be a breakthrough in screening and early detection #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD Recently published in @lancet, we did see benefit in patients with PDL1 >50%. If one year of adjuvant atezolizumab will benefit all patients post resection, and chemotherapy, remains to be seen. It is also important to remember to perform NGS #LCSM @lcsmchat |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @CharuAggarwalMD: Recently published in @lancet, we did see benefit in patients with PDL1 >50%. If one year of adjuvant atezolizumab will benefit all patients post resection, and chemotherapy, remains to be seen. It is also important to remember to perform NGS #LCSM @lcsmchat |
| #LCSM Chat @lcsmchat RT @esinghimd: @CharuAggarwalMD @lcsmchat A3. We had an update on IMPower010 at WCLC21. Adjuvant atezo improved DFS in resected stage 2-3A NSCLC. Will DFS ➡️ OS? Which subgroup of pts, based on PD-L1 %, should receive? #lcsm |
| #LCSM Chat @lcsmchat RT @RManochakian: A3: A3: Probable new standard of care. especially for high #PDL1. Adjuvant #Atezolizumab after adjuvant chemo for resected early stage #NSCLC #LCSM |
| #LCSM Chat @lcsmchat RT @fabiotavora: @smlungpathguy Fabio here, #pulmonarypathologist from Brazil. I still think we can do so much and go so much deeper in tissue than #liquidbiopsy, but am hopeful the latter will be a breakthrough in screening and early detection #LCSM |
| Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation @RManochakian A3: One of The future questions: #Adjuvant immunotherapy vs #neoadjuvant immunotherapy or chemo + immuno. . #LCSM @lcsmchat |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: Recently published in @lancet, we did see benefit in patients with PDL1 >50%. If one year of adjuvant atezolizumab will benefit all patients post resection, and chemotherapy, remains to be seen. It is also important to remember to perform NGS #LCSM @lcsmchat |
| #LCSM Chat @lcsmchat RT @RManochakian: A3: One of The future questions: A3: One of The future questions: #Adjuvant immunotherapy vs #neoadjuvant immunotherapy or chemo + immuno. . #LCSM @lcsmchat |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @RManochakian: A3: One of The future questions: A3: One of The future questions: #Adjuvant immunotherapy vs #neoadjuvant immunotherapy or chemo + immuno. . #LCSM @lcsmchat |
 | Andres F. Cardona @AndresFCardonaZ RT @CharuAggarwalMD: #IMPOWER010 asked the question if adding immunotherapy will add benefit? #LCSM @lcsmchat https://t.co/0fLplu70F0 |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD T4: What did #WCLC21 and #ESMO21 presentations suggest about using immunotherapy when brain metastases are present? #LCSM @lcsmchat |
 | Geoff Oxnard MD @geoff_oxnard RT @CharuAggarwalMD: Early integration of LiquidBiopsy can improve delivery of targeted therapy, and reduce time to treat #BiomarkerTesting #WCLC21 #LCSM @lcsmchat https://t.co/9eUWehicMQ |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @CharuAggarwalMD: T4: T4: What did #WCLC21 and #ESMO21 presentations suggest about using immunotherapy when brain metastases are present? #LCSM @lcsmchat |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: Recently published in @lancet, we did see benefit in patients with PDL1 >50%. If one year of adjuvant atezolizumab will benefit all patients post resection, and chemotherapy, remains to be seen. It is also important to remember to perform NGS #LCSM @lcsmchat |
| Janet Freeman-Daily @JFreemanDaily RT @RManochakian: A3: One of The future questions: A3: One of The future questions: #Adjuvant immunotherapy vs #neoadjuvant immunotherapy or chemo + immuno. . #LCSM @lcsmchat |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: T4: T4: What did #WCLC21 and #ESMO21 presentations suggest about using immunotherapy when brain metastases are present? #LCSM @lcsmchat |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD A4. We have already seen results from CM-9LA and at #WCLC21, we saw subset analyses of patients with treated brain mets (Dr. Carbone) #LCSM @lcsmchat https://t.co/nqS9cUcSJe |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @CharuAggarwalMD: A4. We have already seen results from CM-9LA and at #WCLC21, we saw subset analyses of patients with treated brain mets (Dr. Carbone) #LCSM @lcsmchat https://t.co/nqS9cUcSJe |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: A4. We have already seen results from CM-9LA and at #WCLC21, we saw subset analyses of patients with treated brain mets (Dr. Carbone) #LCSM @lcsmchat https://t.co/nqS9cUcSJe |
| #LCSM Chat @lcsmchat Thank you for joining us @AngelaAchurie @bradylabupenn @SamahAlRehaily #lcsm |
| #LCSM Chat @lcsmchat Thank you for joining us @AndresFCardonaZ @geoff_oxnard #lcsm |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: T4: T4: What did #WCLC21 and #ESMO21 presentations suggest about using immunotherapy when brain metastases are present? #LCSM @lcsmchat |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: A4. We have already seen results from CM-9LA and at #WCLC21, we saw subset analyses of patients with treated brain mets (Dr. Carbone) #LCSM @lcsmchat https://t.co/nqS9cUcSJe |
 | Angela Churie Kallhauge @AngelaAchurie @lcsmchat @bradylabupenn @SamahAlRehaily Thank you. Very inspiring chat. Gives so much hope knowing that finally more is happening for us #lcsm |
| #LCSM Chat @lcsmchat RT @AngelaAchurie: @lcsmchat @bradylabupenn @SamahAlRehaily Thank you. Very inspiring chat. Gives so much hope knowing that finally more is happening for us #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @AngelaAchurie: @lcsmchat @bradylabupenn @SamahAlRehaily Thank you. Very inspiring chat. Gives so much hope knowing that finally more is happening for us #lcsm |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD A4. Patients that have treated brain mets benefit from IO, as well as those without BM #WCLC21 @lcsmchat #lcsm https://t.co/jIMIvQhVHE |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @CharuAggarwalMD: A4. Patients that have treated brain mets benefit from IO, as well as those without BM #WCLC21 @lcsmchat #lcsm https://t.co/jIMIvQhVHE |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: A4. Patients that have treated brain mets benefit from IO, as well as those without BM #WCLC21 @lcsmchat #lcsm https://t.co/jIMIvQhVHE |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD A4. Immunotherapy is safe and effective in patients with treated brain mets, as seen across many other clinical trials. HR represents a reduction in risk of death #Immunotherapy #WCLC21 #LCSM @lcsmchat https://t.co/0atHTftCkr |
| Janet Freeman-Daily @JFreemanDaily There's a lot of #lungcancer research happening, with new biomarkers, drug approvals, and practice-changing studies every year. Very hopeful! #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @CharuAggarwalMD: A4. Immunotherapy is safe and effective in patients with treated brain mets, as seen across many other clinical trials. HR represents a reduction in risk of death #Immunotherapy #WCLC21 #LCSM @lcsmchat https://t.co/0atHTftCkr |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: There's a lot of #lungcancer research happening, with new biomarkers, drug approvals, and practice-changing studies every year. Very hopeful! #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: A4. Patients that have treated brain mets benefit from IO, as well as those without BM #WCLC21 @lcsmchat #lcsm https://t.co/jIMIvQhVHE |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD A4. What about untreated brain metastases? ATEZO-Brain was a clinical trial presented at #WCLC21 with promising early results #lcsm @lcsmchat https://t.co/dSjecZa1U3 |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @CharuAggarwalMD: A4. What about untreated brain metastases? ATEZO-Brain was a clinical trial presented at #WCLC21 with promising early results #lcsm @lcsmchat https://t.co/dSjecZa1U3 |
| Janet Freeman-Daily @JFreemanDaily This is huge! We've wondered for years whether I/O treats the brain effectively in #lungcancer. SO nice to have data! #LCSM |
| Sanjay Mukhopadhyay @smlungpathguy RT @fabiotavora: @smlungpathguy Fabio here, #pulmonarypathologist from Brazil. I still think we can do so much and go so much deeper in tissue than #liquidbiopsy, but am hopeful the latter will be a breakthrough in screening and early detection #LCSM |
| #LCSM Chat @lcsmchat Thank you for joining us @DrFerdowsi @CanaryLauren #lcsm |
| Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation @RManochakian #LCSM @lcsmchat #Immunotherapy can help with brain mets in #NSCLC. Not as good or as often as #TargetedTherapies though. Need More studies/more trials/more biomarkers. |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD RT @JFreemanDaily: There's a lot of #lungcancer research happening, with new biomarkers, drug approvals, and practice-changing studies every year. Very hopeful! #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: This is huge! We've wondered for years whether I/O treats the brain effectively in #lungcancer. SO nice to have data! #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD RT @JFreemanDaily: This is huge! We've wondered for years whether I/O treats the brain effectively in #lungcancer. SO nice to have data! #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @RManochakian: #LCSM @lcsmchat #Immunotherapy can help with brain mets in #NSCLC. Not as good or as often as #TargetedTherapies though. Need More studies/more trials/more biomarkers. |
 | gilberto lopes @GlopesMd RT @JFreemanDaily: There's a lot of #lungcancer research happening, with new biomarkers, drug approvals, and practice-changing studies every year. Very hopeful! #LCSM |
 | Santhosh Ambika @RenoHemonc RT @CharuAggarwalMD: Use of T-DxD is associated with > ORR of 55% > median duration of response of 9.3 months, > median PFS 8.2 months > median OS 17.8 months Bottom Line- most patients benefit. It is important to test! #BioMarker Testing #LCSM @lcsmchat https://t.co/Rnf6sKQ4cM |
| Janet Freeman-Daily @JFreemanDaily RT @RManochakian: #LCSM @lcsmchat #Immunotherapy can help with brain mets in #NSCLC. Not as good or as often as #TargetedTherapies though. Need More studies/more trials/more biomarkers. |
| Angela Churie Kallhauge @AngelaAchurie RT @JFreemanDaily: There's a lot of #lungcancer research happening, with new biomarkers, drug approvals, and practice-changing studies every year. Very hopeful! #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD A4. These results are encouraging, some additional questions remain, that we look forward to being answered in the future #LCSM @lcsmchat https://t.co/YJgmxDFtqS |
| #LCSM Chat @lcsmchat Thank you for joining us @PatelOncology @RenoHemonc #lcsm |
| Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation @RManochakian It’s an era of hope for #NSCLC patients. So much happening indeed. #LCSM @lcsmchat @JFreemanDaily |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD T5: What other #WCLC21 and #ESMO21 presentations or ideas captured you interest? #LCSM @lcsmchat |
| #LCSM Chat @lcsmchat Thank you for joining us @GlopesMd @nuria_dios #lcsm |
 | Denise Cutlip @dennycee Checking in late. Grateful you archive these. #lcsm |
| Janet Freeman-Daily @JFreemanDaily @RManochakian @lcsmchat Immune checkpoint inhibitor (#ICI) drugs may not be as effective treating the brain as #targetedtherapy, but since the two types of drug usually treat different patient populations, it's still a win. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @CharuAggarwalMD: A4. These results are encouraging, some additional questions remain, that we look forward to being answered in the future #LCSM @lcsmchat https://t.co/YJgmxDFtqS |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: A4. Immunotherapy is safe and effective in patients with treated brain mets, as seen across many other clinical trials. HR represents a reduction in risk of death #Immunotherapy #WCLC21 #LCSM @lcsmchat https://t.co/0atHTftCkr |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: There's a lot of #lungcancer research happening, with new biomarkers, drug approvals, and practice-changing studies every year. Very hopeful! #LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: A4. What about untreated brain metastases? ATEZO-Brain was a clinical trial presented at #WCLC21 with promising early results #lcsm @lcsmchat https://t.co/dSjecZa1U3 |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: This is huge! We've wondered for years whether I/O treats the brain effectively in #lungcancer. SO nice to have data! #LCSM |
| #LCSM Chat @lcsmchat RT @RManochakian: #LCSM @lcsmchat #Immunotherapy can help with brain mets in #NSCLC. Not as good or as often as #TargetedTherapies though. Need More studies/more trials/more biomarkers. |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD RT @JFreemanDaily: @RManochakian @lcsmchat Immune checkpoint inhibitor (#ICI) drugs may not be as effective treating the brain as #targetedtherapy, but since the two types of drug usually treat different patient populations, it's still a win. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD RT @JFreemanDaily: @RManochakian @lcsmchat Immune checkpoint inhibitor (#ICI) drugs may not be as effective treating the brain as #targetedtherapy, but since the two types of drug usually treat different patient populations, it's still a win. #LCSM |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: A4. These results are encouraging, some additional questions remain, that we look forward to being answered in the future #LCSM @lcsmchat https://t.co/YJgmxDFtqS |
| #LCSM Chat @lcsmchat RT @RManochakian: It’s an era of hope for #NSCLC patients. So much happening indeed. #LCSM @lcsmchat @JFreemanDaily |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: T5: T5: What other #WCLC21 and #ESMO21 presentations or ideas captured you interest? #LCSM @lcsmchat |
| Janet Freeman-Daily @JFreemanDaily RT @CharuAggarwalMD: A4. These results are encouraging, some additional questions remain, that we look forward to being answered in the future #LCSM @lcsmchat https://t.co/YJgmxDFtqS |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @RManochakian @lcsmchat Immune checkpoint inhibitor (#ICI) drugs may not be as effective treating the brain as #targetedtherapy, but since the two types of drug usually treat different patient populations, it's still a win. #LCSM |
 | Mighty #HeathenSlut Casey🇺🇦🌟 @MightyCasey RT @JFreemanDaily: There's a lot of #lungcancer research happening, with new biomarkers, drug approvals, and practice-changing studies every year. Very hopeful! #LCSM |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD Thank you to everyone for joining us tonight at #LCSM @lcsmchat! |
| Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation @RManochakian @JFreemanDaily @lcsmchat Definitely @JFreemanDaily I tell my patients with #NSCLC on the first visit the same thing. If we find a mutation, will have a good #TargetedTherapy and if we don’t, will have #ImmunoTherapy. Hope and goal of research though to keep finding more #Biomarkers. #LCSM |
| Janet Freeman-Daily @JFreemanDaily RT @RManochakian: @JFreemanDaily @lcsmchat Definitely @JFreemanDaily I tell my patients with #NSCLC on the first visit the same thing. If we find a mutation, will have a good #TargetedTherapy and if we don’t, will have #ImmunoTherapy. Hope and goal of research though to keep finding more #Biomarkers. #LCSM |
 | Tomma Hargraves @TommaHargraves @CharuAggarwalMD @lcsmchat My first #lcsm@lcsmchat… lots of good info! Thanks |
| Lung Cancer Sux @LungCancerSux RT @RManochakian: @JFreemanDaily @lcsmchat Definitely @JFreemanDaily I tell my patients with #NSCLC on the first visit the same thing. If we find a mutation, will have a good #TargetedTherapy and if we don’t, will have #ImmunoTherapy. Hope and goal of research though to keep finding more #Biomarkers. #LCSM |
| Janet Freeman-Daily @JFreemanDaily We have a few minutes left in #LCSM Chat--any closing thoughts? Any guesses on what's next in research? |
| Janet Freeman-Daily @JFreemanDaily I'm seeing more studies for antibody drug conjugates (ADCs)--the antibody targets cancer cells, and then delivers a chemotherapy directly to the cells. #LCSM |
| Timothy Craig Allen, MD, JD, FCAP @TimAllenMDJD I remember a time, not that long ago, when molecular therapy for #lungcancer did not exist. Amazing progress and opportunities! #hope #lcsm |
| #LCSM Chat @lcsmchat #lcsm |
| #LCSM Chat @lcsmchat RT @TommaHargraves: @CharuAggarwalMD @lcsmchat My first #lcsm@lcsmchat… lots of good info! Thanks |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD RT @TimAllenMDJD: I remember a time, not that long ago, when molecular therapy for #lungcancer did not exist. Amazing progress and opportunities! #hope #lcsm |
| #LCSM Chat @lcsmchat RT @CharuAggarwalMD: Thank you to everyone for joining us tonight at #LCSM @lcsmchat! |
| Janet Freeman-Daily @JFreemanDaily @TommaHargraves @CharuAggarwalMD @lcsmchat Glad you were able to join us, Tomma! Most #LCSM chats are more conversational, but tonight we're up against MLB playoffs and football ... |
| Rami Manochakian MD, FASCO 🇺🇸🇸🇾CancerEducation @RManochakian Great #LCSM chat with great colleagues, patients, caregivers & advocates. Thank U all! #TogetherAgainstLungCancer It’s en era of hope for #NSCLC patients. Always remember: #KnowledgeConquersCancer @lcsmchat @JFreemanDaily @CharuAggarwalMD @TimAllenMDJD |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: @TommaHargraves @CharuAggarwalMD @lcsmchat Glad you were able to join us, Tomma! Most #LCSM chats are more conversational, but tonight we're up against MLB playoffs and football ... |
| #LCSM Chat @lcsmchat RT @TimAllenMDJD: I remember a time, not that long ago, when molecular therapy for #lungcancer did not exist. Amazing progress and opportunities! #hope #lcsm |
| Janet Freeman-Daily @JFreemanDaily RT @TimAllenMDJD: I remember a time, not that long ago, when molecular therapy for #lungcancer did not exist. Amazing progress and opportunities! #hope #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: I'm seeing more studies for antibody drug conjugates (ADCs)--the antibody targets cancer cells, and then delivers a chemotherapy directly to the cells. #LCSM |
| #LCSM Chat @lcsmchat RT @RManochakian: @JFreemanDaily @lcsmchat Definitely @JFreemanDaily I tell my patients with #NSCLC on the first visit the same thing. If we find a mutation, will have a good #TargetedTherapy and if we don’t, will have #ImmunoTherapy. Hope and goal of research though to keep finding more #Biomarkers. #LCSM |
| #LCSM Chat @lcsmchat RT @RManochakian: Great #LCSM chat with great colleagues, patients, caregivers & advocates. Thank U all! #TogetherAgainstLungCancer It’s en era of hope for #NSCLC patients. Always remember: #KnowledgeConquersCancer @lcsmchat @JFreemanDaily @CharuAggarwalMD @TimAllenMDJD |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: We have a few minutes left in #LCSM Chat--any closing thoughts? Any guesses on what's next in research? |
| kristen kimball @KimballKristen So much happening! Thank you for this topic tonight. #LCSM |
 | Carol Rizkalla @Carol2Path RT @smlungpathguy: I wonder how far we are from the day when circulating tumor DNA testing (instead of testing for driver mutations in biopsied tissue) will be the first, routine option in stage 4 lung cancer #LCSM |
| Lung Cancer Sux @LungCancerSux Many new faces! Thanks to all! #LCSM |
| Denise Cutlip @dennycee Thank you #LCSM |
| Janet Freeman-Daily @JFreemanDaily Thank you @CharuAggarwalMD for moderating tonight's #LCSM Chat and compiling a great set of tweets about #WCLC21 and #ESMO21 presentations! You had a great first outing as a moderator. |
| Charu Aggarwal, MD, MPH, FASCO @CharuAggarwalMD RT @JFreemanDaily: Thank you @CharuAggarwalMD for moderating tonight's #LCSM Chat and compiling a great set of tweets about #WCLC21 and #ESMO21 presentations! You had a great first outing as a moderator. |
| #LCSM Chat @lcsmchat So many have been watching and liking tweets. I know we haven’t been able to recognize all of you. Very sorry for that. Thank you for joining! #lcsm |
| #LCSM Chat @lcsmchat RT @JFreemanDaily: Thank you @CharuAggarwalMD for moderating tonight's #LCSM Chat and compiling a great set of tweets about #WCLC21 and #ESMO21 presentations! You had a great first outing as a moderator. |
 | Allison Rosen, MS @ARosen380 CALLING ALL AYA’s do you want to help improve reproductive health after cancer? Please take the time to fill this out and please share it to anyone you know! #cancer #ayacsm #crcsm #lcsm #bcsm @AdvocateCollab @EK_Drake @ogcancerpatient |
| Preventive Medicine Bot @PreventiveBot RT @JFreemanDaily: There's a lot of #lungcancer research happening, with new biomarkers, drug approvals, and practice-changing studies every year. Very hopeful! #LCSM |
| Preventive Medicine Bot @PreventiveBot RT @JFreemanDaily: This is huge! We've wondered for years whether I/O treats the brain effectively in #lungcancer. SO nice to have data! #LCSM |
| Preventive Medicine Bot @PreventiveBot RT @TimAllenMDJD: I remember a time, not that long ago, when molecular therapy for #lungcancer did not exist. Amazing progress and opportunities! #hope #lcsm |
 | Arturo LoAIza-Bonilla, MD MSEd @DrBonillaOnc RT @lcsmchat: Thank you for joining us tonight @DrBonillaOnc @BrainTumorDoc #lcsm |
| Arturo LoAIza-Bonilla, MD MSEd @DrBonillaOnc RT @CharuAggarwalMD: T5: T5: What other #WCLC21 and #ESMO21 presentations or ideas captured you interest? #LCSM @lcsmchat |
 | Drew Moghanaki 🐕 @DrewMoghanaki Starting in 15 minutes if you're curious what these people have to say. #lcsm |
#LCSM content from Twitter.